Osudha — Vision, Re-engineered.

The Vision Crisis

People are slowly, irreversibly losing their central vision.

Geographic atrophy is the advanced form of dry age-related macular degeneration. It steals central vision quietly, progressively, and permanently — taking away the ability to read, recognize faces, and navigate daily life.

Recently approved therapies modestly slow disease progression. None stop it. None restore what has already been lost.

The patients living with this disease deserve a therapy that does more.

A Critical Unmet Need

Comparison of normal vision versus vision affected by geographic atrophy

Disease impact · Normal vision vs. Geographic Atrophy

About Osudha

A company built around one goal.

01 — Conviction

We chose a disease, not a category.

Geographic atrophy is not one program among many. It is the program. Our science, our team, and our capital are directed toward a single therapeutic outcome.

02 — Discipline

Rigor before scale.

We are early, and we know it. Our approach is grounded in peer-reviewed biology, in-house computational analysis, and validated genomic datasets — not in vanity milestones.

03 — Patient-First

The eye on the other end.

Behind every line of data is a person losing their ability to read, drive, and recognize a face. That is the brief. Everything else serves it.

The Science

The biology of GA is becoming actionable.

Chronic complement dysregulation and progressive inflammation converge at the retinal pigment epithelium, driving the irreversible cell loss that defines geographic atrophy. Osudha is developing a multi-target bispecific platform designed to interrupt this cascade at its upstream drivers.

Geographic atrophy in the macula — advanced form of dry AMD

Disease biology · Geographic Atrophy / Dry AMD

Modulating the complement cascade to restore balance in geographic atrophy

Disease biology · Geographic Atrophy / Dry AMD

Modulate the complement cascade.

The complement system — a key arm of innate immunity — becomes chronically dysregulated in GA, driving sustained inflammation and progressive retinal damage. Our first therapeutic arm targets upstream complement modulatory factors to restore balance.

Address the cell death axis directly.

Complement dysregulation is one driver. A second independent cell-death pathway in the retinal pigment epithelium amplifies damage. Our second arm — identified through systematic in-house single-cell transcriptomic analysis — targets this axis with precision.

One bispecific platform. Two mechanisms.

Our lead candidate is a bispecific drug designed to engage both disease axes simultaneously within a single molecular framework — a precision-engineered platform, not a polypharmacy approach.

The Osudha Vision Engine

Silicon-led discovery.
Human-led healing.

We don’t search for targets. We map them. Every molecule we advance has been pre-screened against the biology that matters — before a single experiment is run.

In-silico target mapping and molecule screening

From biology to molecule, in a single intelligent loop.

Our discovery engine integrates large-scale single-cell RNA sequencing, public retinal atlases, and proprietary multi-omics data into a unified target landscape.

Candidates are evaluated computationally for binding geometry, tissue selectivity, and pharmacology before a single dollar is committed to the wet lab. The result: capital that goes to molecules with the highest probability of working.

01 — Target Discovery · AI

We map the biology before we touch it.

Targets aren’t guessed — they’re triangulated from the most comprehensive ocular genomic datasets available, weighted by mechanistic relevance to geographic atrophy.

02 — Precision Design · ML

Every molecule, designed for the eye it’s going to.

Computational modeling of binding geometry, tissue selectivity, and pharmacological profile before synthesis. We commit wet-lab capital only to candidates with the highest mechanistic probability of success.

03 — Clinical Validation · Virtual CRO

Real biology. Real data. No vanity infrastructure.

Outcomes from CRO-led preclinical experiments feed directly back into our discovery models. Each iteration is sharper than the last — a closed-loop system designed for capital efficiency.

From Data to Drug

Silicon-led discovery engine: Data Integration to Human Impact

Data Ingestion

Target Mapping

In-Silico Design

Wet-Lab Validation

Loop & Refine

Therapeutic Pipeline

One indication. Disciplined execution.

Our early-stage portfolio is purpose-built for geographic atrophy. Program details are available to qualified investors under a mutual confidentiality agreement.

Indication	Mechanism	Discovery	Preclinical	IND-Enabling	Stage
Lead Geographic Atrophy / Dry AMD Program: OSU-001 · Bispecific platform drug	Complement regulator + Undisclosed second axis				EARLY
Expanded Program OSU-undisclosed · Undisclosed platform extension	Undisclosed				EVAL

Active progress

Forward stage

All programs are early-stage. No regulatory filings to date.

Development Roadmap

From data, to molecule, to validated lead.

Our operating window is designed around clear, capital-efficient inflection points. Each milestone is a decision gate — not a victory lap.

Complete

In-house scRNA-seq atlas built

Complete

Target identification & ranking

In Progress

In-silico construct selection

Upcoming

SPPS synthesis via CRO

Planned

In-vitro proof-of-concept

Planned

In-vivo lead validation

Data Integrity

Every input, verified.

Our discovery engine is only as honest as the data it’s built on. We are uncompromising about source quality, attribution, and reproducibility.

✓

Peer-reviewed primary sources only

All analyses are anchored to peer-reviewed literature with full citation trails — never derivative summaries.

✓

Quality-scored public datasets

Each public dataset is independently scored for sample size, sequencing depth, and annotation quality before integration.

✓

Reproducible analysis pipelines

Every computational step is version-controlled and documented to a standard that supports independent investor diligence.

✓

No hype. No extrapolation.

Outputs are presented at the confidence level the underlying data supports — and not a step beyond.

Osudha was founded on a single conviction: that geographic atrophy is solvable, and that the patients living with it should not have to wait any longer for a therapy that does meaningfully more than slow the inevitable. Our discipline is to earn every step before we take it. Our ambition is to give people back what this disease quietly takes from them — clearly, completely, and with the urgency it deserves.

Founder & Chief Executive Officer

Osudha

Get In Touch

For investors, partners,
and fellow believers.

Osudha is currently operating in stealth and selectively engages with strategic investors, academic partners, and industry collaborators. All inquiries are treated with strict confidentiality. A mutual NDA will be provided upon your expression of interest.

Osudha — bridging discovery, partnership, and patient impact

info@osudha.com

Phone

Available upon request

Confidentiality

All inquiries handled under strict confidentiality. Mutual NDA provided upon engagement.

Form not loading? Open it in a new tab →

Vision shouldn’t fade.

People are slowly, irreversibly losing their central vision.